Agate Medical Investments
VC Fund
Tel Aviv, Israel
Agate Medical Investments is a VC fund in Tel Aviv focused on Health Care and Medical Device. Agate Medical Investments LP specializes in mid venture; late stage; and buyout investments in mature companies. The fund seeks to invest in medical technology companies and specialized healthcare sector. The fund invests in medical technology companies that are innovating in such areas as diagnostics, prevention, alleviation and treatment ofserious illnesses with large market potential; medical devices, and in healthcare services and initiatives related to healthcare infrastructure, the provision of medical services and remote medicine - for example, HMOs, diagnostic imaging centers, surgical centers, women's health, managed care, and senior citizens' homes.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 14%
Last updated:
For AI agents: llms.txt
Industries Agate Medical Investments invests in
Stages Agate Medical Investments invests in
Countries Agate Medical Investments invests in
Investment Focus
Industry
- Health Care 7 (100%)
- Medical Device 5 (71%)
- Medical 3 (43%)
- Biotechnology 3 (43%)
- Therapeutics 2 (29%)
Stage
- Series C 3 (43%)
- Series B 1 (14%)
- Series E 1 (14%)
- Series F 1 (14%)
- Funding Round 1 (14%)
Country
- Israel 3 (43%)
- United States 2 (29%)
- South Korea 1 (14%)
- Switzerland 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Brainsgate
|
BrainsGate's platform technology involves electrical stimulation of the Spheno-Palatine Ganglion (SPG), a nervous center known to increase cerebral blood flow. BrainsGate is exploring several applications for its technology, and is currently focusing on treatment of acute ischemic stroke. Building on its technology, the Company has developedthe ISS, based on a miniature electrode implanted at the roof of the mouth in a bed side, minimally invasive, local anesthesia procedure comparable to dental treatment. In 2008, the company completed ImPACT-1, a pilot clinical trial for acute ischemic stroke with promising results. In 2011 the Company completed a 300 patients RCT pivotal trial that further substantiated the safety and efficacy of its treatment for acute ischemic stroke patients. BrainsGate is currently running the ImpACT-24b, a multi-national, randomized, double-blind, sham-controlled pivotal study to assess the safety and efficacy of its treatment for stroke patients in a 24-hour window. | $14M / Series F / Dec 06, 2020 | |
CLEW Medical
|
CLEW Medical specializes in providing healthcare providers and administrators with high-accuracy predictive clinical analytics. Their innovative analytics engine detects deterioration in real-time and delivers predictive warnings during all phases of a patient’s ICU stay. Driven by innovative prediction models derived from Big Data analysis and anadvanced high-dimensional analytics technique, CLEW's predictive platform has the flexibility to manage large patient populations without losing individualized treatment needs. CLEW's team represents decades of success in assisting healthcare institutions and other enterprises achieve their goals by exploiting breakthrough research and technologies. | $10M / Series B / Jan 15, 2020 | |
MST Medical Surgery Technologies
|
Medical Surgery Technologies (MST) was founded in 2005 by Ziv Tamir and Moti Sholev, entrepreneurs with extensive experience in medical devices. MST leads the field of surgical analytics with its core image analytics technology designed to empower and automate the surgical environment, with a focus on medical robotics and computer-assisted surgery(MRCAS). The company's core technology is a software-based image analytics information platform powered by advanced visualization, scene recognition, artificial intelligence, machine learning and data analytics. The platform is positioned to enable the operating room of the future through real-time image analytics, connectivity and automation, providing value-added functionality for surgeon, provider and patient. MST’s initial offering is AutoLap™, the only robotic image-guided laparoscope positioning system. Powered by MST’s image-analysis software, AutoLap™ interacts with the surgeon’s movements in the surgical cavity, guiding the robotic laparoscope positioner in real time, offering the surgeon full and natural control of the surgical procedure and an optimal field of view. | $12.5M / Series C / Jul 01, 2015 | |
AngioSlide
|
Angioslide, founded in 2005 by Eran Hirszowicz and Amos Nahir, is a privately-held medical device company. The company has developed a unique Embolic Capture Angioplasty™ (ECA) device family that combines standard balloon angioplasty with debris removal capabilities through its suction mechanism. Physicians using the PROTEUS™ device can now captureand remove embolic particles during angioplasty procedures. | $3M / Series E / May 01, 2015 | |
Peptron
|
Peptron is a biotech company developing a wide range of peptide and small molecule based drugs to treat chronic and life-threatening disorders. Its initial focus is to provide long-term cure for neurodegenerative, cancer and endocrine related diseases. Peptron integrates the extensive experience of peptide research, drug development and expertisein drug delivery technologies for more than 15 years combined with a patients-focused approach driven by excellence. | Jan 01, 2014 | |
SENSIMED
|
Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best beused in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment.Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland. | Series C / Oct 09, 2012 | |
Valeritas
|
Valeritas is a medical technology company committed to developing and commercializing innovative drug delivery solutions that contribute to clinical and humanistic outcomes for patients, with an initial focus on the treatment of diabetes. Valeritas' medical technologies portfolio is headlined by the h-Patch technology. The first use of theh-Patch technology will be the V-Go disposable insulin delivery device for continuous delivery both at a preset basal rate and for on-demand bolus dosing at mealtimes.The V-Go is a simple-to-use, once-daily, disposable insulin delivery device that provides a preset basal rate and on-demand bolus dosing for mealtime coverage via a mealtime insulin. The V-Go will enable the millions suffering from Type 2 diabetes to conveniently and discreetly deliver insulin throughout the day bolus dose on-demand around mealtimes.The h-Patch technology is also being developed to serve as a launching platform for applications across a wide spectrum of medical needs. | $150M / Series C / Sep 12, 2011 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Agate Medical Investments invest in?
Agate Medical Investments invests primarily in Health Care, Medical Device and Medical startups, most often at Series C and Series B stage. Most of the 7 investments tracked by Shizune back companies in Israel. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Agate Medical Investments last invest?
The most recent investment recorded for Agate Medical Investments closed in Dec 2020. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
